A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895 on ClinicalTrials.gov · last registry update 2026-05-12
An unusually large phase 3: 905 participants, more than double the 424 typical for the stage. Due to report November 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 905
- Started
- 2025-04-25
- Primary completion
- 2026-11 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Hemoglobin A1c (HbA1c)
Conditions studied
Type 1 Diabetes · Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.